EMA recommends new approach to benefit:risk assessment of drugs
This article was originally published in SRA
Executive Summary
The European Medicines Agency has published its first report on a five-part project that aims to improve and standardise the way in which drug regulatory authorities in the European Union assess the relative benefits and risks of medicinal products1.